Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06724016 | Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors | PHASE1 | RECRUITING | 292 | — | — | Dec 11, 2024 | Jul 1, 2031 | Dec 17, 2025 | 7 | United States, South Korea |
To evaluate safety and tolerability of HM16390 as a single agent and in combination with pembrolizumab
To evaluate safety and tolerability of HM16390 as a single agent, and in combination with pembrolizumab
| Arm | Type | Description |
|---|---|---|
| HM16390 | EXPERIMENTAL | HM16390 Monotherapy |
| HM16390 + pembrolizumab | EXPERIMENTAL | HM16390 in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| HM16390 | DRUG | HM16390 will be administered subcutaneously using syringes on Day 1 of every 3-week treatment cycle |
| pembrolizumab | DRUG | Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle |
Key Inclusion Criteria: * Have a histologically and/or cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit. * Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patient...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |